Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

NCT03335943 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

800

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG: CDA-2 (Cell Differentiation Agent 2)

Sponsor

Chinese Society of Hematology

Collaborators

[object Object]